Register for free to listen to this article
Listen with Speechify
0:00
1:00
TURKU, Finland—Two Finnish companies, BioCis Pharma Oy andOy Lx Therapies Ltd., have merged to create Laurantis Pharma Oy, aclinical-stage specialty pharmaceutical development company.
 
Founded in 2003, BioCis is a clinical-stage drug-developmentcompany focused on unmet needs such as inflammation, allergy and cancer. Itsdevelopment programs address dermatology, ophthalmology and urology. BioCis'patented ProtoDynamic Therapy technology regulates intracellular pH, includingthe proton or hydrogen ion concentration inside cells. The company has a PhaseII program in atopic dermatitis, a Phase I program in bladder cancer and apreclinical program in dry eye syndrome.
 
Oy Lx Therapies, founded in 2008, is a drug discoverycompany focused on developing gene-mediated therapies for the prevention andtreatment of diseases of lymphatic vasculature. The initial focus of thecompany is on breast cancer-related lymphedema, a relatively commoncomplication of breast cancer treatment for which there is currently no cure oreffective treatment.
 
 
In connection with the creation of the new company, Dr. RikuRautsola, was appointed president and CEO of Laurantis Pharma. In addition,Inveni Capital and Helsinki University Funds made an investment in LaurantisPharma.
 
 
"We are very excited about having the capacity to a build acompetitive specialty pharmaceutical company with a strong technology base.Laurantis Pharma is well-positioned to reach several significant clinicalmilestones for its lead products in the next two to three years," Rautsola saidin a statement. "This provides the unique opportunity to build Laurantis Pharmafrom an early clinical development company to a successful specialtypharmaceutical company in the coming years."
 
Lasse Leino, previously CEO of BioCis Pharma, will becomechief operating officer of Laurantis Pharma.

Related Topics

Published In

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Clear sample tubes are shown in a clear tote with red lids in a sample prep robot with a blue and silver industrial lab background.

The crucial role of sample preparation in biotherapy manufacturing

Discover how better sample preparation can unlock improved assay accuracy and analytical results.
A black mosquito is shown on pink human skin against a blurred green backdrop.

Discovering deeper insights into malaria research

Malaria continues to drive urgent research worldwide, with new therapies and tools emerging to combat the parasite’s complex lifecycle and global burden.
Three burgundy round and linear conformations of oligonucleotides are shown against a black background.

Accelerating RNA therapeutic testing with liver microphysiological platforms

Researchers can now study oligonucleotide delivery and efficacy in a system that models a real human liver.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue